A theory too revolutionary to seem plausible? And yet the experiment is a success!

 

30 years of basic research in France, Sweden and the USA on cancer allowed a scientist, Dominique Joubert, to put forward a theory, at the time considered heresy: The "tumor reversion of a solid cancer".

 

In 2003 Dominique Joubert, PhD then research director at Inserm, thought he had found the target that should allow him to demonstrate the accuracy of his theory. From the first experiment, the theory was confirmed!

 

It still needs to be explained, that is to say, to understand the mechanisms... and to come up with a therapeutic solution.

 

To transform a lab demonstration into a solution for the patient, you sometimes have to count only "on yourself and your loved ones"!

 

In 2006, there was enough data to propose moving on to the development of a therapeutic solution and the filing by Inserm of a first patent. Except that, if the patent is filed, the research institution that laid the scientific foundations is not made to develop.

 

Dominique Joubert therefore takes his head out of the lab, embarks his scientific partner, his nephew and her husband, in the creation of a biotechnology company, without funds, without experience in the field.

 

In only 5 years the therapeutic molecule is generated.

 

It takes an infinite amount of time and resources to convince!

​

In 2011, unable to go any further without substantial financial aid, the therapy project will be sold to one of the 13 manufacturers who have entered into negotiations. But the team will continue to develop on behalf of this manufacturer.

 

In 2014, the manufacturer (the Servier Group), entangled in problems unrelated to this development, withdrew.

 

Dominique Joubert sold what he could to finance the resumption of the project and resumed his pilgrim's staff. A world tour would not allow the therapeutic solution to be financed for clinical entry.

 

It was then decided to develop a test to help with early cancer detection by targeting the same protein that is specific and essential to cancer. This would also demonstrate that the target was the right one.

 

At the end of 2017, the test was developed and registered with the CE mark.

 

At the end of 2019, clinical trials and a year of real-life testing, both for international distribution and for the incorporation of the test into the health system, confirm the interest in helping with screening and monitoring the effectiveness of therapies.

 

And when a solution is available, the medical profession must still be available!

 

At the beginning of 2020, the launch of the distribution of the test and... COVID! Everything is closed to cancer, the cancer that kills so many people has passed behind the current crisis. The medical profession does not have/no longer has the time to implement such an innovative device that shakes up practices.

 

Never mind, in January 2023, Dominique Joubert and her husband decide to donate all the shares they hold in the company that developed her solutions and to sell their collection of contemporary art to finance the creation of an Institute. This institute will aim to help the medical profession incorporate innovation in the fight against cancer. Any type of innovation, and not just the revolution of targeting hPG80 that she initiated.

​

To ensure that the solutions benefit patients, the Cancer Innovation Institute will propose protocols to the medical profession.

 

February 4, 2023. An endowment fund is created, with the dual mission of raising money and creating the "Cancer Innovation" Institute (website opens on February 4). The first mission of this institute will be to establish protocols for the use of new cancer screening tools, including hPG80.